News
MDXH
0.8930
-9.31%
-0.0917
Mdxhealth Earnings Call: Prostate Pivot Amid Pressure
TipRanks · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras
Reuters · 2d ago
MDxHealth price target lowered to $5 from $9 at Lake Street
TipRanks · 2d ago
MDxHealth price target lowered to $1.50 from $7 at TD Cowen
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (TYRA) and MDxHealth (MDXH)
TipRanks · 2d ago
MDxHealth downgraded to Market Perform from Outperform at William Blair
TipRanks · 2d ago
MDxHealth price target lowered to $4 from $7 at BTIG
TipRanks · 2d ago
MDxHealth to exit the Resolve mdx business
TipRanks · 2d ago
MDxHealth sees FY26 revenue $110M-$115M, consensus $118.6M
TipRanks · 2d ago
BTIG Remains a Buy on MDxHealth (MDXH)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: MDxHealth (MDXH) and Ibio (IBIO)
TipRanks · 2d ago
Mdxhealth Exits Resolve Business, Refocuses on Prostate Cancer as Q1 2026 Revenue Rises 13%
TipRanks · 2d ago
BRIEF-Mdxhealth Reports Q1-2026 Results
Reuters · 2d ago
MDxHealth reports Q1 EPS (17c) vs. (19c) last year
TipRanks · 2d ago
MDxHealth SA GAAP EPS of -$0.17 misses by $0.02, revenue of $27.38M misses by $3.42M
Seeking Alpha · 2d ago
MDxHealth Q1 FY26 operating loss widens 59% to USD 7.3 million; revenue rises 13% to USD 27.4 million
PUBT · 2d ago
MDXHEALTH SA <MDXH.O> Q1 SHR VIEW $-0.15, REV VIEW $30.6 MLN -- LSEG IBES DATA
Reuters · 2d ago
Mdxhealth Reports Q1-2026 Results
Barchart · 3d ago
Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI), PolyPid (PYPD) and MDxHealth (MDXH)
TipRanks · 3d ago
Weekly Report: what happened at MDXH last week (0504-0508)?
Weekly Report · 5d ago
More
Webull provides a variety of real-time MDXH stock news. You can receive the latest news about Mdxhealth Sa through multiple platforms. This information may help you make smarter investment decisions.
About MDXH
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.